FDA has accepted a supplemental New Drug Application and granted priority review for Keytruda (pembrolizumab), an anti-PD-1 therapy.
On Nov. 5, as the American people expressed their will, electing Donald Trump to a second term, I started to wonder what my friends in oncology were thinking.
